HomeInsightsStock Comparison

Cipla Ltd vs Gufic Biosciences Ltd Stock Comparison

Cipla Ltd vs Gufic Biosciences Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1600 as of 02 Aug 11:09.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Gufic BioSciences Ltd changed from 33 on March 2024 to 0 on March 2025 . This represents a CAGR of -100.00% over 2 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Gufic BioSciences Ltd changed from ₹ 2839 crore on March 2024 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 2 years.
  • The revenue of Cipla Ltd for the Jun '25 is ₹ 7216 crore as compare to the Mar '25 revenue of ₹ 7019 crore. This represent the growth of 2.8% The revenue of Gufic BioSciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 205.41 crore. This represent the decline of -100%.
  • The ebitda of Cipla Ltd for the Jun '25 is ₹ 2036 crore as compare to the Mar '25 ebitda of ₹ 1827 crore. This represent the growth of 11.47% The ebitda of Gufic BioSciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 26.77 crore. This represent the decline of -100%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1292 crore over 9 quarters. This represents a CAGR of 12.23% The net profit of Gufic BioSciences Ltd changed from ₹ 20.62 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Gufic BioSciences Ltd changed from 2.14 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Gufic BioSciences Ltd

  • Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients.
  • Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network.
  • The Company is ranked among the top 100 pharmaceutical companies in India. Gufic is a leading manufacturer of lyophilized injections in India, with a state-of-the-art automated lyophilization plant located in Navsari, Gujarat.
  • The Company was incorporated in July, 1984.
  • The recent addition of the Indore manufacturing facility has further solidified Gufic's position as one of the world's largest producers of lyophilized injections.

Cipla Ltd News Hub

News

Cipla gains after Q1 PAT rises 10% YoY to Rs 1,298 crore

Profit before tax (PBT) stood at Rs 1,769.93 crore in Q1 FY26, marking an 9.84% increase f...

Read more

25 Jul 2025 15:25

News

Cipla to conduct board meeting

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025. Powere...

Read more

02 Jul 2025 10:19

News

Cipla allots 43,396 equity shares under ESOP

Cipla has allotted 43,396 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

27 Jun 2025 11:02

News

Cipla Ltd spurts 0.42%, up for fifth straight session

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up ...

Read more

11 Jun 2025 13:00

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

Gufic BioSciences Ltd News Hub

News

Gufic BioSciences appoints senior management personnel

Gufic BioSciences has appointed Rajesh Kaul as Senior President ' Sparsh Cluster, Senior M...

Read more

02 Jul 2025 18:34

News

Board of Gufic BioSciences recommends final dividend

Gufic BioSciences announced that the Board of Directors of the Company at its meeting held...

Read more

30 May 2025 20:18

News

Gufic BioSciences to announce Quarterly Result

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 30 May 2...

Read more

24 May 2025 18:18

News

Gufic BioSciences to announce Quarterly Result

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 Febru...

Read more

08 Feb 2025 14:21

News

Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr

Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expense...

Read more

18 Nov 2024 11:09

News

Gufic Biosciences Q2 PAT drops 6% YoY to Rs 22 cr

Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expense...

Read more

15 Nov 2024 12:29

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Gufic BioSciences Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Gufic BioSciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Gufic BioSciences Ltd

Which company has a larger market capitalization, Cipla Ltd or Gufic BioSciences Ltd?

Market cap of Cipla Ltd is 121,259 Cr while Market cap of Gufic BioSciences Ltd is 3,852 Cr

What are the key factors driving the stock performance of Cipla Ltd and Gufic BioSciences Ltd?

The stock performance of Cipla Ltd and Gufic BioSciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Gufic BioSciences Ltd?

As of August 2, 2025, the Cipla Ltd stock price is INR ₹1501.2. On the other hand, Gufic BioSciences Ltd stock price is INR ₹384.2.

How do dividend payouts of Cipla Ltd and Gufic BioSciences Ltd compare?

To compare the dividend payouts of Cipla Ltd and Gufic BioSciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions